Search Patents
  • Modified PEDV spike protein
    Patent number: 11464852
    Abstract: The present invention relates to a nucleic acid molecule encoding a modified porcine epidemic diarrhea virus (PEDV) spike (S) protein and the PEDV (S) protein thereof. Further, the present invention relates to immunogenic compositions comprising said modified PEDV spike protein and methods for immunizing a subject comprising the administration of said immunogenic composition to a subject.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: October 11, 2022
    Inventors: Veljko Nikolin, Andreas Gallei
  • MODIFIED PEDV SPIKE PROTEIN
    Publication number: 20200093919
    Abstract: The present invention relates to a modified porcine epidemic diarrhea virus (PEDV) spike (S) protein. Further, the present invention relates to immunogenic compositions comprising said modified PEDV spike protein and methods for immunizing a subject comprising the administration of said immunogenic composition to a subject.
    Type: Application
    Filed: September 18, 2019
    Publication date: March 26, 2020
    Inventors: Veljko NIKOLIN, Andreas GALLEI
  • Peptide Therapeutics Against SARS-COV-2 Spike Protein
    Publication number: 20230218743
    Abstract: Proteinaceous therapeutics, such as antibodies and fusion proteins, for preventing, reducing the occurrence of, and/or treating a SARS-CoV-2 infection in a subject are provided herein. The methods provided herein include administering to a subject an antigen binding fragments (Fab fragment) or antibody that binds to the S ARS-CoV-2 Spike protein, ACE2 decoy peptides that bind to the SAILS-CoV-2 Spike protein, and/or a DNA construct encoding an anti-Spike Fab fragment or ACE2 decoy peptide.
    Type: Application
    Filed: September 6, 2022
    Publication date: July 13, 2023
    Inventors: Jay Gardner NELSON, Oleksandr BUZKO, Wendy M. HIGASHIDE, Kayvan NIAZI, Clifford Anders OLSON, Patrick SOON-SHIONG, Shiho TANAKA
  • MODIFIED S2 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
    Publication number: 20220213148
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 865. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Application
    Filed: May 6, 2020
    Publication date: July 7, 2022
    Inventors: Annika KRAEMER-KUEHL, Thomas Min Stephan
  • MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
    Publication number: 20200354410
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Application
    Filed: May 6, 2020
    Publication date: November 12, 2020
    Inventors: Annika KRAEMER-KUEHL, Thomas Min STEPHAN, Hans-Christian PHILIPP
  • RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-COV-2 SPIKE PROTEIN AND USES THEREOF
    Publication number: 20230310583
    Abstract: Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotid sequence encoding a SARS-CoV-2 spike protein or nucleocapsid protein. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 spike protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against SARS-CoV-2 as well as the prevention of COVID-19.
    Type: Application
    Filed: May 6, 2021
    Publication date: October 5, 2023
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Weina SUN, Florian KRAMMER, Adolfo GARCIA-SASTRE, Peter PALESE
  • Modified S1 subunit of the coronavirus spike protein
    Patent number: 11512115
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 29, 2022
    Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
  • MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
    Publication number: 20230340028
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Application
    Filed: November 28, 2022
    Publication date: October 26, 2023
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Annika KRAEMER-KUEHL, Thomas Min STEPHAN, Hans-Christian PHILIPP
  • Modified S1 subunit of the coronavirus spike protein
    Patent number: 11964999
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: April 23, 2024
    Assignee: Boehringer Ingelheim Vetmedia GmbH
    Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
  • EXTRACELLULAR VESICLES HARBORING A SPIKE PROTEIN, NUCLEIC ACIDS FOR PRODUCING THE SAME, AND METHOD OF IMMUNIZING A SUBJECT AGAINST SARS-CoV-2 USING THE SAME
    Publication number: 20220096624
    Abstract: A nucleic acid including (i) a sequence of a S gene coding for a Spike protein and (ii) a sequence coding for a pilot peptide which interacts with ESCRT proteins. Also, extracellular vesicles, in particular exosomes, harboring at their external surface a Spike protein, obtainable by transfecting cells with the nucleic acid. Further, a method of immunizing a subject against a virus of the Orthocoronavirinae subfamily, in particular against SARS-CoV-2, by DNA prime-protein boost using the nucleic acid and the extracellular vesicles of the invention.
    Type: Application
    Filed: September 29, 2020
    Publication date: March 31, 2022
    Applicant: CILOA
    Inventors: Bernadette Nadine TRENTIN, Katarzyna POLAK, Zaïne El Abiddine Robert MAMOUN
  • DNA sequences encoding infectious bronchitis virus spike protein
    Patent number: 5032520
    Abstract: The problem of diagnosis and typing of infectious bronchitis virus in poultry has been solved and important progress made towards an IBV vaccine by this invention. DNA complementary to the region of genomic IBV RNA which codes for a spike protein polypeptide comprising the S1 polypeptide (containing antigenic determinants) or the S2 polypeptide (containing means for anchoring the spike protein to the viral membrane) has been made. It can be carried by a cloning vector, incorporated in a host and cloned. It can also be cloned in a poxvirus which is used to transfect mammmalian cells. Such cells express an artificial spike protein polypeptide.
    Type: Grant
    Filed: November 4, 1986
    Date of Patent: July 16, 1991
    Assignee: National Research Development Corporation
    Inventors: Matthew M. Binns, Michael E. G. Boursnell, Thomas D. K. Brown, Fiona M. Tomley
  • ANTIBODIES TO SARS-CORONAVIRUS (COVID-19) S1 SPIKE PROTEIN
    Publication number: 20210388065
    Abstract: The present invention provides recombinant monoclonal antibodies that bind to the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2 or COVID-19) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to SARS-CoV-2 spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing SARS-CoV-2 activity, thus providing a means of treating or preventing COVID-19 infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the SARS-CoV-2 spike protein for use in treating COVID-19 infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the SARS-CoV-2 spike protein.
    Type: Application
    Filed: April 15, 2020
    Publication date: December 16, 2021
    Applicants: ACTIVE MOTIF SHANGHAI LIMITED, SHANGHAI PUBLIC HEALTH CLINICAL CENTER, FUDAN UNIVERSITY, SHANGHAI PUBLIC HEALTH CLINICAL CENTER
    Inventors: Yanan LU, Fei LAN, Jianqing XU, Xi ZHAO, Longfei DING, Yongheng WANG, Jinkai WAN, Shenghui XING, Joseph FERNANDEZ
  • MODIFIED POLYNUCLEOTIDES ENCODING THE SARS-COV-2 SPIKE PROTEIN FOR SAFER DESIGNS OF CORONAVIRUS VACCINES
    Publication number: 20240100152
    Abstract: Recombinant polynucleotides including a nucleic acid sequence encoding an engineered SARS-CoV-2 spike protein (S12) or an immunogenic fragment thereof, in which the engineered spike protein or immunogenic fragment includes one or more mutations in the S2 segment of the S12 ectodomain. Vaccines, pharmaceutical compositions, and methods of use of the polynucleotides, vaccines, and pharmaceutical compositions in treating, alleviating, or managing SARS-CoV-2 infection and/or one or more symptoms thereof.
    Type: Application
    Filed: September 6, 2023
    Publication date: March 28, 2024
    Inventors: Pei Tang, Tommy Stevens Tillman, Yan Xu
  • HUMANIZED ANTIBODY FOR SARS-CoV-2 SPIKE PROTEIN INFUSION
    Publication number: 20220323345
    Abstract: An embodiment provides a method for treatment of the COVID-19 virus, including: preparing an intravenous infusion, wherein the intravenous infusion comprises at least one humanized monoclonal antibody against the SARS-CoV-2 spike protein; introducing the intravenous infusion to a patient; forming a virion antibody complex, wherein the virion antibody comprises the at least one humanized monoclonal antibody against the SARS-CoV-2 spike protein; and monitoring the virion antibody complex from a sample of a body fluid. Other aspects are described and claimed.
    Type: Application
    Filed: April 11, 2022
    Publication date: October 13, 2022
    Inventors: Qiang Chen, Mitchell Steven Felder
  • HAPTENIZED CORONAVIRUS SPIKE PROTEINS
    Publication number: 20230149534
    Abstract: The disclosure provides an immunogenic composition comprising an haptenized Spike protein (S protein) or fragment thereof from a coronavirus and at least one pharmaceutically acceptable carrier, wherein the coronavirus comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Further disclosed are methods of using the haptenized S proteins from coronavirus or immunizing a subject against coronavirus infection.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 18, 2023
    Inventors: David Berd, James Passin
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20210283245
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Application
    Filed: May 26, 2020
    Publication date: September 16, 2021
    Inventors: Kayvan Niazi, Thomas King
  • ANTI COVID-19 THERAPIES USING NUCLEOCAPSID AND SPIKE PROTEINS
    Publication number: 20220023415
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 27, 2022
    Inventor: Thomas H. King
  • SARS-2 SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE
    Publication number: 20230310582
    Abstract: The invention provides SARS-2 spike protein designs and uses thereof.
    Type: Application
    Filed: April 14, 2021
    Publication date: October 5, 2023
    Inventors: Rory Henderson, Kevin Saunders, Barton F. Haynes, Priyamvada Acharya
  • EXPRESSION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE PROTEIN SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME
    Publication number: 20230002780
    Abstract: A plant produced vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is provided where the Spike protein of the virus is expressed in a plant by introducing into a plant a construct comprising a promoter preferentially directing expression to seed of said plant, a nucleic acid encoding the Spike protein and a nucleic acid targeting expression to the endoplasmic reticulum of the plant. The plant expresses the 51 polypeptide at levels of at least 10 mg/kg of seed of said plant. When orally administered to an animal, a protective response is observed including a serum antibody response.
    Type: Application
    Filed: June 24, 2022
    Publication date: January 5, 2023
    Inventors: John Howard, Erin Egelkrout
  • METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS
    Publication number: 20170096455
    Abstract: The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.
    Type: Application
    Filed: March 20, 2015
    Publication date: April 6, 2017
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Ralph Baric, Sudhakar Agnihothram, Boyd Yount
Narrow Results

Filter by US Classification